...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.
【24h】

Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.

机译:免疫组化标记物在原发性和转移性恶性黑色素瘤中的表达:使用组织芯片技术对70例患者进行的比较研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Melanoma can show a broad spectrum of immunoreactivity and exhibit aberrant expression of antigens or changes in immunophenotype, particularly at metastatic sites. We studied 70 primary melanomas and their metastases with a broad panel of immunohistochemical markers using a tissue microarray technique to determine possible antigenic shift between the primary lesions and their metastases. Representative tissue cores were taken and processed from each case, and the tissue microarrays were stained by standard methods using antibodies to vimentin, bcl-2, CD117, carcinoembryonic antigen, epithelial membrane antigen, S-100 protein, HMB-45, cytokeratin AE1/AE3, Melan-A, TTF-1, CD99, and tyrosinase. Histologically, all the melanomas were of the classic epithelioid type. A slight increase in the expression of Melan-A was noted in metastatic lesions as opposed to the primary tumors (63% vs. 48.4%). Expression of other melanoma-associated markers, including S-100 protein and tyrosinase was only slightly decreasedat metastatic sites as opposed to the primary tumor. Increased aberrant expression of epithelial-associated markers, including epithelial membrane antigen and cytokeratin AE1/AE3 was also noted in the metastases. bcl-2, CD117, and TTF-1 also showed a modest increase in antigenic expression at metastatic sites over the primary lesions. The results of this study demonstrated minimal antigenic shift between primary and metastatic melanoma for some of the more conventional melanocytic markers, it showed increased expression of aberrant markers and oncogene expression at metastatic sites.
机译:黑色素瘤可表现出广泛的免疫反应性,并表现出抗原的异常表达或免疫表型的变化,特别是在转移部位。我们使用组织微阵列技术研究了70种原发性黑色素瘤及其转移,并采用了广泛的免疫组织化学标记物,以确定原发性病变与其转移之间可能的抗原转移。从每种情况中取出代表性的组织核心并进行处理,并使用抗波形蛋白,bcl-2,CD117,癌胚抗原,上皮膜抗原,S-100蛋白,HMB-45,细胞角蛋白AE1 /的抗体通过标准方法对组织微阵列进行染色AE3,Melan-A,TTF-1,CD99和酪氨酸酶。从组织学上讲,所有黑色素瘤都是经典的上皮样类型。与原发性肿瘤相比,转移性病变中Melan-A的表达略有增加(63%比48.4%)。与原发性肿瘤相反,其他黑色素瘤相关标志物(包括S-100蛋白和酪氨酸酶)的表达在转移部位仅轻微降低。转移中还注意到上皮相关标志物,包括上皮膜抗原和细胞角蛋白AE1 / AE3的异常表达增加。 bcl-2,CD117和TTF-1在原发灶的转移部位也显示出适度的抗原表达增加。这项研究的结果表明,对于一些较常规的黑素细胞标记,原发性和转移性黑素瘤之间的抗原转移最小,它显示了转移性部位异常标志物和癌基因表达的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号